165 related articles for article (PubMed ID: 37620821)
21. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
[TBL] [Abstract][Full Text] [Related]
22. Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse.
Sterling RK; Smith PG; Brunt EM
J Clin Gastroenterol; 2013 Feb; 47(2):182-7. PubMed ID: 23059409
[TBL] [Abstract][Full Text] [Related]
23. The role of non-invasive scores in determining the liver fibrosis in NAFLD and psoriatic patients.
Neagoe CD; Farmazon AS; Amzolini AM; Singer CE; Ianoşi SL; Tutunaru CV; Genunche-Dumitrescu AV; Ianoşi NG; Păun I; Leru PM; Tica OS; Popescu M
Rom J Morphol Embryol; 2020; 61(2):503-511. PubMed ID: 33544802
[TBL] [Abstract][Full Text] [Related]
24. Elevated AST-to-platelet ratio index is associated with increased all-cause mortality among HIV-infected adults in Zambia.
Vinikoor MJ; Sinkala E; Mweemba A; Zanolini A; Mulenga L; Sikazwe I; Fried MW; Eron JJ; Wandeler G; Chi BH
Liver Int; 2015 Jul; 35(7):1886-92. PubMed ID: 25581487
[TBL] [Abstract][Full Text] [Related]
25. Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States.
Rebeiro PF; Emond B; Rossi C; Bookhart BK; Shah A; Caron-Lapointe G; Lafeuille MH; Donga P
J Int AIDS Soc; 2023 Jun; 26(6):e26123. PubMed ID: 37306118
[TBL] [Abstract][Full Text] [Related]
26. Liver Fibrosis Assessment in a Cohort of Greek HIV Mono-Infected Patients by Non-Invasive Biomarkers.
Androutsakos T; Schina M; Pouliakis A; Kontos A; Sipsas N; Hatzis G
Curr HIV Res; 2019; 17(3):173-182. PubMed ID: 31549590
[TBL] [Abstract][Full Text] [Related]
27. Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium.
Byonanebye DM; Polizzotto MN; Neesgaard B; Sarcletti M; Matulionyte R; Braun DL; Castagna A; de Wit S; Wit F; Fontas E; Vehreschild JJ; Vesterbacka J; Greenberg L; Hatleberg C; Garges H; Gallant J; Volny Anne A; Öllinger A; Mozer-Lisewska I; Surial B; Spagnuolo V; Necsoi C; van der Valk M; Mocroft A; Law M; Ryom L; Petoumenos K;
HIV Med; 2022 Sep; 23(8):895-910. PubMed ID: 35233903
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.
Siddiqui MS; Yamada G; Vuppalanchi R; Van Natta M; Loomba R; Guy C; Brandman D; Tonascia J; Chalasani N; Neuschwander-Tetri B; Sanyal AJ;
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1877-1885.e5. PubMed ID: 30616027
[TBL] [Abstract][Full Text] [Related]
29. Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral Therapy.
Surial B; Chammartin F; Damas J; Calmy A; Haerry D; Stöckle M; Schmid P; Bernasconi E; Fux CA; Tarr PE; Günthard HF; Wandeler G; Rauch A;
Clin Infect Dis; 2023 Sep; 77(5):729-737. PubMed ID: 37157869
[TBL] [Abstract][Full Text] [Related]
30. Modified AST to platelet ratio index improves APRI and better predicts advanced fibrosis and liver cirrhosis in patients with non-alcoholic fatty liver disease.
Huang C; Seah JJ; Tan CK; Kam JW; Tan J; Teo EK; Kwek A; Wong YJ; Tan M; Ang TL; Kumar R
Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101528. PubMed ID: 33268036
[TBL] [Abstract][Full Text] [Related]
31. Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized Trial.
Dharan NJ; Neuhaus J; Rockstroh JK; Peters L; Gordin F; Arenas-Pinto A; Emerson C; Marks K; Hidalgo J; Sarmento-Castro R; Stephan C; Kumarasamy N; Emery S; Matthews GV;
Hepatology; 2019 Mar; 69(3):1135-1150. PubMed ID: 30298608
[TBL] [Abstract][Full Text] [Related]
32. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis.
Polyzos SA; Goulis DG; Kountouras J; Mintziori G; Chatzis P; Papadakis E; Katsikis I; Panidis D
Hormones (Athens); 2014; 13(4):519-31. PubMed ID: 25402369
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and dynamics of NAFLD-associated fibrosis in people living with HIV in Vienna from first presentation to last follow-up.
Schwarz C; Chromy D; Bauer D; Duong N; Schmidbauer VU; Schwarz M; Mandorfer M; Rieger A; Trauner M; Gschwantler M; Reiberger T
Wien Klin Wochenschr; 2023 Aug; 135(15-16):420-428. PubMed ID: 36576556
[TBL] [Abstract][Full Text] [Related]
34. Integrase inhibitors in late pregnancy and rapid HIV viral load reduction.
Rahangdale L; Cates J; Potter J; Badell ML; Seidman D; Miller ES; Coleman JS; Lazenby GB; Levison J; Short WR; Yawetz S; Ciaranello A; Livingston E; Duthely L; Rimawi BH; Anderson JR; Stringer EM;
Am J Obstet Gynecol; 2016 Mar; 214(3):385.e1-7. PubMed ID: 26928154
[TBL] [Abstract][Full Text] [Related]
35. Hepatic steatosis and nonalcoholic fatty liver disease are common and associated with cardiometabolic risk in a primary prevention cohort of people with HIV.
Lake JE; Taron J; Ribaudo HJ; Leon-Cruz J; Utay NS; Swaminathan S; Fitch KV; Kileel EM; Paradis K; Fulda ES; Ho KS; Luetkemeyer AF; Johnston CD; Zanni MV; Douglas PS; Grinspoon SK; Lu MT; Fichtenbaum CJ;
AIDS; 2023 Nov; 37(14):2149-2159. PubMed ID: 37503623
[TBL] [Abstract][Full Text] [Related]
36. Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease.
Qadri S; Ahlholm N; Lønsmann I; Pellegrini P; Poikola A; Luukkonen PK; Porthan K; Juuti A; Sammalkorpi H; Penttilä AK; D'Ambrosio R; Soardo G; Leeming DJ; Karsdal M; Arola J; Kechagias S; Pelusi S; Ekstedt M; Valenti L; Hagström H; Yki-Järvinen H
J Clin Endocrinol Metab; 2022 Apr; 107(5):e2008-e2020. PubMed ID: 34971370
[TBL] [Abstract][Full Text] [Related]
37. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran.
Amernia B; Moosavy SH; Banookh F; Zoghi G
BMC Gastroenterol; 2021 Dec; 21(1):453. PubMed ID: 34861841
[TBL] [Abstract][Full Text] [Related]
38. Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL.
Gianotti N; Lorenzini P; Cozzi-Lepri A; De Luca A; Madeddu G; Sighinolfi L; Pinnetti C; Santoro C; Meraviglia P; Mussini C; Antinori A; d'Arminio Monforte A;
J Antimicrob Chemother; 2019 Sep; 74(9):2732-2741. PubMed ID: 31173639
[TBL] [Abstract][Full Text] [Related]
39. Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease.
Prasoppokakorn T; Chan WK; Wong VW; Pitisuttithum P; Mahadeva S; Nik Mustapha NR; Wong GL; Leung HH; Sripongpun P; Treeprasertsuk S
World J Gastroenterol; 2022 Apr; 28(15):1563-1573. PubMed ID: 35582126
[TBL] [Abstract][Full Text] [Related]
40. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial.
Brown EA; Minnich A; Sanyal AJ; Loomba R; Du S; Schwarz J; Ehman RL; Karsdal M; Leeming DJ; Cizza G; Charles ED
JHEP Rep; 2023 Apr; 5(4):100661. PubMed ID: 36866389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
